Our vision is: To find the cause of and a cure for brain tumours while improving the quality of life for those affected. Research is the key to achieving our vision.
Brain Tumour Foundation of Canada is happy to announce our partnership with Kindred Foundation, Cancer Research Society, Phoebe Rose Rocks Foundation, Miracle Marnie, Childhood Cancer Canada and Tali’s Fund. Together we have joined forces to support the Defeating Embryonal Cancer in Young People Together (DECRYPT) Research Grant, which will open in early 2023. This grant will provide $600,000 to one Canadian research project focused on childhood embryonal brain tumours.
On behalf of the CNO Meeting Organizing Committee we are looking forward to seeing you in our Nation’s Capital for the 20th Biennial Canadian Neuro-Oncology Meeting. We are planning a robust conference agenda which will feature breaking advances in Neuro-Oncology research and Neurosurgical techniques.
Brain Tumour Foundation of Canada partners with the Brain Tumor Funders’ Collaborative to extend the impact of research dollars.
Five North American funding organizations make up the Brain Tumor Funders’ Collaborative. The organization includes Brain Tumour Foundation of Canada along with five other non-profit, philanthropic and advocacy organizations from the United States. By working together we can accelerate progress in brain tumor research. The groups have worked together to fund two previous initiatives (details below) and are now exploring a third joint project. When this is finalized, the projects details, and any applicable calls for applications will be posted here.
The members of the Brain Tumour Funders’ Collaborative are:
In January 2019 the BTFC announced $3 million in grants to four multi-institutional teams of researchers and clinicians studying immunotherapy in primary brain tumours. Read the Press Release here.
The four funded projects will examine vaccination strategies, the tumour’s micro-environment, anti-tumour T-cells, and personalized immunotherapy approaches. They were selected during a multi-stage review process from more than 79 responses to the BTFC call for proposals.
The following institutions will be receiving $750,000 BTFC grants over the next three years:
Active vaccination and the timing of checkpoint blockade dictate effective immunotherapy for glioblastoma
David Geffen School of Medicine at UCLA
Project Manager: Robert Prins
Harnessing the brain tumour immune-microenvironment to enhance therapeutic efficacy
McGill University
Project Manager: Daniela Quail
Interrogating anti-tumor T-cells To develop adoptive cell transfer (ACT) Immunotherapy for pediatric high-grade gliomas
UPMC Children’s Hospital of Pittsburgh
Project Manager: Gary Kohanbash
Three dimensional immuno-genomics approach to personalized neoantigen-based immunotherapy
University of California, San Francisco
Project Manager: Joseph Costello
